4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies

Multiparametric MRI (PI-RADS) & Biopsy Strategies

Over the past decade, the diagnostic pathway for prostate cancer has undergone a paradigm shift. The historical practice of performing blind, systematic transrectal ultrasound (TRUS)-guided 10-to-12-core biopsies based solely on an elevated PSA level has been replaced by an image-guided diagnostic pathway centered on pre-biopsy multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy.

---

Pre-Biopsy mpMRI: Landmark Trial Evidence

The historical systematic TRUS biopsy protocol harbored two severe structural flaws: substantial underdetection of clinically significant prostate cancer (csPCa) (failing to sample anterior, apical, and midline lesions in up to 30% of cases) and rampant overdetection of indolent, clinically insignificant tumors (ISUP Grade Group 1), which generated diagnostic anxiety and unnecessary overtreatment.

Two landmark clinical trials redefined international standards of care:

The PROMIS Trial (Lancet 2017)

The prospective, multicentre PROMIS study evaluated 576 biopsy-naive men with elevated PSA levels (up to 15 ng/mL). All patients underwent 1.5T mpMRI followed by both standard 10-to-12 core TRUS biopsy and a rigorous 5-mm template transperineal mapping (TPM) biopsy as the definitive histological reference standard:

• Sensitivity for csPCa (Gleason >= 4+3 or cancer core length >= 6 mm): mpMRI demonstrated 93% sensitivity (95% CI 88–96%), compared to only 48% sensitivity (95% CI 42–55%) for standard TRUS biopsy.
• Negative Predictive Value (NPV): mpMRI achieved an 89% NPV, compared to 74% for TRUS biopsy.
• Clinical Impact: MRI triage could avoid primary biopsy in 27% and reduce insignificant-cancer diagnoses by 5%; MRI-directed subsequent sampling could detect up to 18% more significant cancers than the standard pathway. These were pathway estimates: significant cancer was still present in some MRI-negative men, so clinical risk assessment and follow-up remain essential.

The PRECISION Trial (NEJM 2018)

The multicentre randomized PRECISION trial evaluated 500 biopsy-naive men randomized to either standard systematic 10-to-12-core TRUS biopsy without MRI versus mpMRI followed by targeted biopsy (up to 4 cores per target) only if a suspicious lesion (PI-RADS score >= 3) was identified:

• Clinically Significant Cancer Detection: MRI-targeted biopsy detected significantly more csPCa than standard TRUS biopsy (38% vs 26%, p = 0.005).
• Overdiagnosis Reduction: MRI-targeted biopsy diagnosed significantly fewer clinically insignificant (ISUP Grade Group 1) cancers (9% vs 22%, p < 0.001).
• Biopsy Avoidance: 28% of men in the MRI arm had non-suspicious imaging (PI-RADS 1–2) and did not undergo biopsy in the trial pathway.

---

PI-RADS v2.1 Scoring and Sequence Dominance

The Prostate Imaging - Reporting and Data System, Version 2.1 (PI-RADS v2.1) standardizes the acquisition, interpretation, and reporting of prostate mpMRI on 1.5T or 3T platforms. mpMRI incorporates three core imaging components:

1. T2-Weighted (T2W) Imaging: Provides high anatomical spatial resolution, delineating zonal anatomy, the surgical pseudocapsule, neurovascular bundles, and seminal vesicles.
2. Diffusion-Weighted Imaging (DWI) / Apparent Diffusion Coefficient (ADC): Evaluates the Brownian motion of water molecules. Hypercellular malignant tissue restricts water diffusion, appearing hypointense (dark) on quantitative ADC maps and hyperintense (bright) on ultra-high b-value DWI sequences (b >= 1400–2000 s/mm²).
3. Dynamic Contrast-Enhanced (DCE) MRI: Assesses microvascular permeability and neoangiogenesis through rapid, serial post-gadolinium acquisitions. Positive DCE means focal enhancement earlier than or contemporaneous with adjacent normal tissue, corresponding to a suspicious T2W/DWI finding; washout is not required.

Zonal Anatomy & Sequence Dominance

The diagnostic interpretation of mpMRI depends fundamentally on anatomical zone:

PROSTATE ZONAL ANATOMY & PI-RADS DOMINANCE
├── Peripheral Zone (PZ)   ──> Dominant Sequence: DWI / ADC
│                                Tie-breaker for Score 3: DCE
└── Transition Zone (TZ)   ──> Dominant Sequence: T2-Weighted (T2W)
                                T2W 2 + DWI >=4 -> 3
                                T2W 3 + DWI 5   -> 4

1. Peripheral Zone (PZ) — Dominant Sequence: DWI/ADC

• PI-RADS 1: Normal ADC and high b-value DWI.
• PI-RADS 2: Linear or wedge-shaped hypointensity on ADC and/or linear or wedge-shaped hyperintensity on high b-value DWI.
• DWI Score 3: Focal ADC hypointensity and/or high-b DWI hyperintensity. Marked abnormality may occur on either sequence, but not both. The overall PZ category then depends on DCE.
  • The Role of DCE as Tie-Breaker: In the peripheral zone, DCE functions exclusively as a tie-breaker for PI-RADS 3 lesions. If DCE is negative (no focal early enhancement), the lesion remains PI-RADS 3. If DCE is positive (early, focal enhancement corresponding to the DWI lesion), the lesion is upgraded to PI-RADS 4.
• PI-RADS 4: Marked focal hypointensity on ADC and marked hyperintensity on high b-value DWI, measuring < 1.5 cm in greatest dimension.
• PI-RADS 5: Same criteria as PI-RADS 4, but measuring >= 1.5 cm in greatest dimension OR exhibiting definite extraprostatic extension (EPE) or invasive behavior.

2. Transition Zone (TZ) — Dominant Sequence: T2W

• T2W Score 1: Normal TZ or a round, completely encapsulated typical BPH nodule.
• T2W Score 2: Mostly encapsulated nodule, a homogeneous circumscribed nodule without a capsule, or homogeneous mild hypointensity between nodules.
• T2W Score 3: Heterogeneous signal with obscured margins, including findings not meeting scores2,4 or5.
  • DWI Adjustment: T2W2 with DWI≥4 becomes overall PI-RADS3. T2W3 remains3 with DWI≤4 and upgrades to PI-RADS4 only with DWI5.
• PI-RADS 4: Non-circumscribed, homogeneous, lenticular or ill-defined low T2 signal intensity with "erased charcoal" appearance, measuring < 1.5 cm in greatest dimension.
• PI-RADS 5: Same features as PI-RADS 4, but measuring >= 1.5 cm in greatest dimension OR exhibiting definite extraprostatic extension.

---

Biopsy Indications and Clinical Decision Algorithms (EAU 2025/2026 Guidelines)

The clinical management following pre-biopsy mpMRI depends on the assigned PI-RADS score and patient-specific risk profiles in accordance with current EAU Guidelines (Sections 5.5.8 & 5.6.4):

1. MRI-Positive Findings (PI-RADS >= 4)

• Clinical Significance: Significant-cancer detection increases with PI-RADS category, but also depends on PSA density and the tested population. Categories4–5 warrant tissue assessment in the appropriate clinical setting.
• EAU Recommendation: For MRI-positive findings (PI-RADS >= 4), clinicians should combine targeted biopsy with perilesional sampling (weak recommendation).
• Sampling Rationale: Perilesional cores sample tissue around the MRI target, addressing tumour extension and targeting imprecision while limiting the number of cores. The remainder of the gland cannot be assumed benign because MRI is negative there. Decide whether additional systematic sampling is appropriate from the overall risk and diagnostic context.

2. Indeterminate MRI Findings (PI-RADS 3)

• Clinical Significance: Detection rates for csPCa range from 15% to 25%. A uniform biopsy-all approach is inappropriate.
• EAU Recommendation:
  • Omit Biopsy and Offer PSA Monitoring: When clinical suspicion of csPCa is very low, defined as PSA density < 0.10 ng/mL/cc and no family history of prostate cancer.
  • Consider Targeted Biopsy with Perilesional Sampling: When clinical suspicion is present or elevated (e.g., PSAD >= 0.10 ng/mL/cc, positive family history, or a palpable DRE abnormality).

3. MRI-Negative Findings (PI-RADS <= 2)

• Clinical Significance: Negative MRI lowers risk but does not exclude significant cancer. Its negative predictive value depends on PSA density, prior biopsy findings and the underlying prevalence of disease.
• EAU Recommendation:
  • Omit Biopsy and Offer PSA Monitoring: In patients where clinical suspicion of csPCa is low, defined as PSA density < 0.20 ng/mL/cc and no family history, omit biopsy and offer structured PSA monitoring as part of a shared decision-making process.
  • Biopsy Consideration: Consider systematic biopsy when clinical suspicion remains high despite negative imaging (e.g., PSAD >= 0.20 ng/mL/cc, strong family history, or a distinct palpable nodule on DRE).

---

Biopsy Routes: Transperineal (TP) versus Transrectal (TR)

The choice of anatomical access represents a foundational patient-safety mandate in contemporary uro-oncology:

Transrectal Ultrasound-Guided (TRUS) Biopsy

In standard transrectal biopsy, the biopsy needle traverses the colonized rectal mucosa into the prostate gland 10 to 14 times. Despite empiric antibiotic prophylaxis, rectal flora (particularly Escherichia coli) is inoculated directly into the prostatic parenchyma and bloodstream:

• Infection Risk: Transrectal biopsy carries greater infectious risk from rectal flora; the rate depends on local resistance and prophylaxis. EAU cites pooled sepsis rates of approximately 0.9% for TR versus 0.1% for TP.
• Prevention: European fluoroquinolone restrictions include suspension of the prostate-biopsy prophylaxis indication. For TR biopsy, use rectal povidone-iodine preparation plus appropriate antibiotics: EAU favours culture-targeted prophylaxis, with augmented prophylaxis as another option. Follow local susceptibility and regulatory guidance.
• Hemorrhagic Complications: Direct rectal puncture induces rectal bleeding (hematochezia) in up to 15–20% of patients.

Transperineal (TP) Biopsy

In transperineal biopsy, the needle approaches the prostate through the surgically prepped perineal skin (chlorhexidine or povidone-iodine), entirely bypassing the rectum:

• Low Infection Risk: Avoiding rectal puncture substantially reduces infectious complications, but does not eliminate sepsis.
• Antimicrobial Stewardship: Because the rectal wall is not breached, EAU gives a weak recommendation to omit perioperative antibiotics in TP patients without infection risk factors, providing a powerful countermeasure against global multi-drug resistance.
• Superior Anterior Sampling: The transperineal needle trajectory aligns parallel to the long axis of the prostate, providing direct, unhindered access to the anterior fibromuscular stroma, anterior transition zone, and prostate apex—regions notoriously prone to false-negative sampling with transrectal needle guides.

---

Biopsy Targeting Modalities and Sampling Strategies

When a suspicious lesion is identified on mpMRI, tissue acquisition is executed using one of three targeted techniques:

1. Cognitive (Visual) Registration: The operator reviews the mpMRI report and images prior to biopsy and mentally estimates the lesion's spatial location on real-time 2D ultrasound. While cost-effective, it is highly operator-dependent and prone to targeting error for lesions < 10 mm or those located deep in the anterior gland.
2. Software-Based MRI-Ultrasound Fusion: Pre-acquired 3D mpMRI contours are digitally aligned with real-time transrectal or transperineal ultrasound using specialized tracking hardware. Registration algorithms are either rigid (mapping fixed spatial geometry) or elastic (compensating for prostate deformation caused by the ultrasound probe). This is the current standard of care in high-volume centres.
3. In-Bore MRI-Guided Biopsy: The patient is placed inside the diagnostic MRI gantry, and biopsy needles are deployed directly under real-time MRI guidance. While offering confirmed needle placement, it is time-consuming, expensive, and resource-intensive.

Targeted Biopsy with Perilesional Sampling vs. Universal Systematic Biopsy

The urological paradigm has moved away from mandating universal 10-to-12 core systematic biopsies in all patients:

• Diagnostic Trade-Off: Adding systematic cores can detect MRI-invisible clinically significant cancer as well as additional Grade Group1 disease. EAU reports that omitting systematic sampling from a targeted-only strategy would miss approximately 16% of detected GG≥2 cancers in biopsy-naive cohorts. This supports careful sampling decisions rather than treating all background cores as unnecessary.
• The Modern Standard — Targeted Biopsy plus Perilesional Sampling: Current EAU guidelines recommend targeted biopsy combined with perilesional sampling for PI-RADS >= 4 lesions. Take at least three to five cores to sample the MRI lesion adequately, with additional regional/perilesional cores to address surrounding tumour and targeting error. The optimal number and spatial extent of perilesional cores are not fully standardized.
• Systematic Biopsy Role: A full systematic template is not required in every MRI-positive patient. It may be selectively considered in patients with persistent high clinical suspicion, multifocal imaging suspicion, or in repeat biopsy scenarios where initial targeted sampling did not resolve clinical concern.

---

PI-RADS v2.1 Zonal Scoring Criteria & EAU Management Algorithm